Hepatoprotective role of neutrosecR on hepatic damage induced by combination of zidovudine and combined anti-tuberculous agents in rats

Tokai Journal of Experimental and Clinical Medicine

Volumn 36, Issue 2, 2011, Pages 31-36

  Awodele, Olufunsho ^a   Agbaje, Esther O ^a   Adesina, Enitan A ^a   Akintonwa, Alade ^a  

^a UNIVERSITY OF LAGOS   (Nigeria)

Author keywords

Fixed dose combined anti tuberculous agents; Hepatic damage; Neu trosec; Oxidative stress; Zidovudine

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CATALASE; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; GLUTATHIONE; LIVER PROTECTIVE AGENT; MALONALDEHYDE; NEUTROSEC; PROTEIN; SCAVENGER; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; ZIDOVUDINE; AMINO ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIOXIDANT; PROTECTIVE AGENT; VITAMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; LIPID PEROXIDATION; LIVER LEVEL; LIVER PROTECTION; MODULATION; NONHUMAN; RAT; TOXIC HEPATITIS; ANIMAL; DIET SUPPLEMENTATION; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; LIVER; LIVER FUNCTION TEST; METABOLISM;

AMINO ACIDS; ANIMALS; ANTI-HIV AGENTS; ANTIOXIDANTS; ANTITUBERCULAR AGENTS; CATALASE; DIETARY SUPPLEMENTS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; LIVER; LIVER FUNCTION TESTS; PROTECTIVE AGENTS; RATS; VITAMINS; ZIDOVUDINE;

EID: 79960419703     PISSN: 03850005     EISSN: 21852243     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Michael P. Holt. Mechanisms of Drug-Induced Liver Injury. The AAPS Journal, 2005; 1: E48-E54.
2. Cynthia I. Mechanisms of Drug-Induced Liver Injury. The AAPS Journal, 2005; 1: E48-E54.
3. Zimmerman HJ. "Drug-induced liver disease". Drugs 1978; 16(1): 25-45.
4. Tasduq SA, Peerzada K, Koul S, Bhat R, Johri RK. Biochemical manifestation of anti-tuberculosis drugs induced hepatotoxicity and the effect of Silymarin. Hepatol Res, 2005; 31: 132-135.
5. Awodele O, Akintonwa A, Osunkalu V. O. & Coker H. A. B. -Modulatory activity of antioxidants against the toxicity of rifam-picin in vivo. Rev. Inst. Med. Trop. São Paulo, 2010; 52(1): 43-46.
6. Sharma SK. Antituberculosis drugs and hepatotoxicity. Infect Genet Evol 2004; 4: 167-170.
7. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The Growing Burden of Tuberculosis: Global Trends and Interactions with the HIV Epidemic Archives of Internal Medicine 2003; 163: 1009-21.
8. WHO. (World Health Organization) Global tuberculosis control: WHO/ HTM/ TB/ 2006. 362. Geneva.
9. Kuznetsova A. TB/HIV Co-Infection in the Penitentiary. Presentation at the TB/HIV Workshop "Collaboration between National TB Programme and National HIV/AIDS Programme," Moscow: 2004; December 14-15.
10. Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. J Am Med Assoc; 1995; 273: 220-6.
11. WHO. (World Health Organization) TB/HIV: A Clinical Manual. Russian Edition. 143 pages. Strategic Framework to Decrease the Burden of TB/HIV. Geneva, 2002.
12. Palella FJ, Delaney KM, Moorman AC. Declining morbidity and mortality among patients with. N Engl J Med 1998; 338: 853-860.
13. Reisler RB, Han C, Burman WJ. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr; 2003; 34: 379-86.
14. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet; 2000; 356: 1423-30.
15. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol; 2006; 44: S132-S139.
16. Martinez E, Blanco JL, Arnaiz JA. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral-therapy. AIDS; 2001; 15: 1261-8.
17. Sulkowski MS. Hepatitis C in the HIV-infected person. Ann Intern Med; 2003; 138: 197-207.
18. Chapman TM, Plosker GL, Perry CM. Fosamprenavir: a review of its use in the management of antiretroviral therapy naive patients with HIV infection. Drugs; 2004; 64: 210124.
19. Dubin G, Braffman MN. Zidovudine-induced hepatotoxicity. Ann Intern Med.1989; 1; 110(1): 85-86.
20. Gradon JD, Chapnick EK, Sepkowitz DV. Zidovudine-induced hepatitis. J Intern Med 1992; 231: 317-318.
21. Shriner K., Goetz MB. Severe hepatotoxicity in a patient receiving both acetaminophen and zidovudine. Am J Med: 1992; 93: 94-6.
22. Wassef M, Keiser P. Hypersensitivity to zidovudine: report of a case of anaphylaxis and review of the literature. Clin Infect Dis; 1995; 20: 1387-9.
23. Wang JY, Hsueh PR, Jan IS. "Empirical treatment with a fluoro-quinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas" Thorax 2006; 61(10): 903-8.
24. WHO. Treatment of tuberculosis. Guidelines for national programmes. 3rd ed. Geneva: World Health Organization; 2003. WHO/CDS/TB/2003. 313.
25. Hong Kong. Chest Service/British Medical Research Council. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy. Am Rev Resp Dis; 1989; 140: 1618-1622.
26. Du Toit, L. C., Pillay, V. and Danckwerts, M. P. Tuberculosis chemotherapy: current drug delivery approaches. Respiratory Research, 2006; 7: 118.
27. Bangalore S, Kamalakkannan G, Parker S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007; 120: 713-719.
28. Beers RF, Seizer IW. A spectrophotometric method for measuring breakdown of hydrogen peroxide by catalase. Journal of Biological Chemistry, 1952; 195, 133.
29. Beuge JA, Aust SD. The thiobarbituri acid assay. Methods Enzymol 1978; 52, 306.
30. Soon, Y. Y., Tan, B. K. H. Evaluation of the hypoglycemic and antioxidant activities of Morinda officinalis in streptozocin-induced diabetic rats. Singapore Medical Journal 2002; 43, 077-085.
31. Ebuehi OAT, Ajuluchukwu AE, Afolabi OT, Ebuehi OM, Akinwande AI. Catalase activity, lipid peroxidation, Cholesterol and Triglyceride levels in Alloxan induced Diabetes Mellitus in Female and Male rats. Nig. Qt. J. Hosp. Med 2009; 19, 15-19.
32. Daley CL, Small PM, Scheeter GF, Schoolink GK, McAdam RA, Jacobs WR, Hopewell PC. An outbreak of tuberculosis with accelerated progression among persons infected with the Human immunodeficiency virus. An analysis using restriction - fragment - length polymorphism. N. Eng J. Med. 1992; 326: 231-235.
33. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, Ong KR, Kilburn JO, Dudley SW, Castro KG. An outbreak of multidrug resistant tuberculosis among hospitalized patients with a acquired immunodeficiency syndrome. N. Eng. l J. Med. 1992; 326: 1514-1521.